CD52 Monoclonal Antibody (YTH34.5), Invitrogen™
Manufacturer: Thermo Scientific
Select a Size
| Pack Size | SKU | Availability | Price |
|---|---|---|---|
| Each of 1 | PIMA516999-Each-of-1 | In Stock | ₹ 87,086.50 |
PIMA516999 - Each of 1
In Stock
Quantity
1
Base Price: ₹ 87,086.50
GST (18%): ₹ 15,675.57
Total Price: ₹ 1,02,762.07
Antigen
CD52
Classification
Monoclonal
Concentration
1 mg/mL
Formulation
PBS with no preservative
Gene Accession No.
P31358
Gene Symbols
CD52
Immunogen
human lymphocytes
Quantity
500 μg
Primary or Secondary
Primary
Target Species
Human, Rhesus Monkey
Product Type
Antibody
Isotype
IgG2b
Applications
Cytotoxicity Assay, ELISA, Flow Cytometry, Immunohistochemistry, Immunohistochemistry (Frozen), Immunohistochemistry (Paraffin), Immunoprecipitation, Western Blot
Clone
YTH34.5
Conjugate
Unconjugated
Gene
CD52
Gene Alias
AI463198; B7; B7-Ag; cambridge pathology 1 antigen; CAMPATH-1; CAMPATH-1 antigen; Cd52; CD52 antigen; CD52 antigen (CAMPATH-1 antigen); CD52 molecule; CDW52; CDW52 antigen (CAMPATH-1 antigen); CLS1; Epididymal secretory protein E5; epididymis secretory sperm binding protein Li 171mP; he5; HEL-S-171mP; human epididymis-specific protein 5; Lymphocyte differentiation antigen B7; Mb7
Host Species
Rat
Purification Method
Protein A
Regulatory Status
RUO
Gene ID (Entrez)
1043, 714429
Content And Storage
-20° C, Avoid Freeze/Thaw Cycles
Form
Liquid
Related Products
Description
- This product is a low-endotoxin, preservative-free formulation
- For FACS analysis, use 10 μL of the suggested working dilution to label 1x10^6 cells in 100 μL
- A suggested positive control for immunohistochemical applications is tonsil
- For cytotoxic assays, use human serum as a complement source
- Rat anti Human CD52 antibody, clone YTH34.5 reacts with the human CD52 antigen, also known as CAMPATH-1
- CD52, also known as CAMPATH-1 antigen, is a glycoprotein that is expressed on the surface of various immune cells, including T and B lymphocytes, natural killer cells, and monocytes
- It is involved in the regulation of immune responses and is being studied as a potential therapeutic target in various diseases, including multiple sclerosis, chronic lymphocytic leukemia, and autoimmune disorders
- CD52 is the target of alemtuzumab, a monoclonal antibody that is used to treat these conditions by depleting immune cells that express CD52.